Last reviewed · How we verify
conbercept, PRN
Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).
Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). Used for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | conbercept, PRN |
|---|---|
| Sponsor | Chengdu Kanghong Biotech Co., Ltd. |
| Drug class | VEGF/PlGF inhibitor (recombinant fusion protein) |
| Target | VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Conbercept functions as a VEGF/PlGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc region of human immunoglobulin G1. This design allows it to sequester circulating VEGF and PlGF, preventing their interaction with endogenous receptors and thereby inhibiting pathological angiogenesis and vascular permeability. It is administered via intravitreal injection for retinal diseases.
Approved indications
- Neovascular age-related macular degeneration (wet AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- Evaluation of RC28-E Injection in Diabetic Macular Edema (PHASE2)
- Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization (NA)
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (PHASE3)
- Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration (PHASE4)
- Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy (PHASE4)
- Initial Versus Delayed PDT Combination With Conbercept in PCV (PHASE4)
- Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma (EARLY_PHASE1)
- Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |